Molecular Partners Ag (MOLN) Research & Development (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Research & Development of -$12061.3 for Q1 2026, up 9.03% year-on-year from -$11062.0 in Q1 2025, and down 100.02% on a QoQ basis from $50.3 million in Q4 2025.
Molecular Partners Ag (MOLN) Research & Development (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Research & Development for 7 consecutive years, with -$12061.3 the latest figure, recorded in Q1 2026.
- Quarterly Research & Development rose 9.03% year-over-year to -$12061.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.3 million (down 9.36% YoY) and the FY2025 annual result came in at $50.3 million, down 9.36% from the prior year.
- Research & Development retreated to -$12061.3 in Q1 2026 per MOLN's latest filing, from $50.3 million in the prior quarter.
- Over the last five years, Research & Development for MOLN reached as high as $55.5 million in Q4 2024 and fell as low as -$13.1 million in Q2 2022.
- A 5-year average of $11.0 million and a median of -$12539.3 in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development sank 187.59% — and 2024, when it jumped 99.89%.
- Year by year, Research & Development stood at $52.7 million in 2022, then increased by 4.4% to $55.0 million in 2023, then increased by 0.89% to $55.5 million in 2024, then retreated by 9.36% to $50.3 million in 2025, then tumbled by 100.02% to -$12061.3 in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$12061.3, $50.3 million, and -$10410.9 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -12,061.31 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12,061.31 |
| Dec 31, 2025 | 50.33 Mn |
| Sep 30, 2025 | -10,410.91 |
| Jun 30, 2025 | -12,931.67 |
| Mar 31, 2025 | -13,259.14 |
| Dec 31, 2024 | 55.53 Mn |
| Sep 30, 2024 | -12,539.31 |
| Jun 30, 2024 | -14,471.52 |
| Mar 31, 2024 | -16,158.70 |
| Dec 31, 2023 | 55.04 Mn |
| Sep 30, 2023 | -13,140.89 |
| Jun 30, 2023 | -12.94 Mn |
| Mar 31, 2023 | -13,725.36 |
| Dec 31, 2022 | 52.72 Mn |
| Sep 30, 2022 | -11,903.61 |
| Jun 30, 2022 | -13.05 Mn |
| Mar 31, 2022 | 15,670.40 |
| Dec 31, 2021 | 60.47 Mn |
| Sep 30, 2021 | -12,723.21 |
| Jun 30, 2021 | -34.65 Mn |